At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.

Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.

Zoledronic Acid

No Treatment

Total

Subject self reported date of birth used to calculate age

Sex: Female, Male

Region of Enrollment

An imaging method known as dual energy x-ray absorptiometry (DXA) was used to obtain BMD of the distal femur and proximal tibia by using a customized research software program supplied by the manufacturer. This measurement will be the primary determinant (dependent measure) of difference among the treatment and control groups, and they will be followed over time at the previously specified time points.

Bone Mineral Density (BMD) at the Distal Femur and Proximal Tibia at Baseline and Month 12.

An imaging method known as dual energy x-ray absorptiometry (DXA) was used to obtain BMD of the total hip.

hypercalciuria/krvarenje

Zoledronic Acid Administration in Acute Spinal Cord Injury

Najkompletnija baza ljekovitog bilja potpomognuta znanošću